|
Post by JHam on Apr 5, 2017 13:18:23 GMT
Just got home and am listening to the playback. I'll let you know if there is anything new to update.
|
|
|
Post by JHam on Apr 5, 2017 13:41:15 GMT
Good presentation, but nothing really new to report.
|
|
|
Post by bernstein on Apr 10, 2017 18:21:41 GMT
Im not a chart technical but i think breakout is imminent ,what do you guys think ?
|
|
|
Post by JHam on Apr 10, 2017 19:28:16 GMT
Im not a chart technical but i think breakout is imminent ,what do you guys think ? Not sure. Besides the volume what leads you to believe that?
|
|
|
Post by bernstein on Apr 11, 2017 16:16:47 GMT
yes ,looks like i was right nice move so far
|
|
|
Post by bernstein on Apr 26, 2017 16:32:05 GMT
Need to break the MA(50) at $4.24 then $5+ coming
|
|
|
Post by JHam on Apr 26, 2017 17:45:13 GMT
Need to break the MA(50) at $4.24 then $5+ coming $5+? What makes you think so?
|
|
|
Post by bernstein on Apr 28, 2017 12:17:44 GMT
just intuition buddy ... New Investor bought a MASSIVE stake of 1.3 Million shares 5.5% , now the majority of the 22.9 million shares outstanding held by Insiders and Institutions which is a very good sign .GL 13g filing ih.advfn.com/p.php?pid=nmona&article=74443449
|
|
|
Post by bernstein on May 8, 2017 13:10:07 GMT
|
|
|
Post by JHam on May 8, 2017 13:18:30 GMT
Good news. Not too unusual to see a company receive FTD though so I won't be surprised if any gains don't hold. Breakthrough designation on the other hand, would be huge news.
|
|
|
Post by JHam on May 8, 2017 13:34:47 GMT
Just sold my position for a meager 14% gain. Nothing massive, but I'll take it. I feel confident that I'll be able to buy back cheaper than what I sold for in the next few days.
|
|
|
Post by bernstein on May 9, 2017 10:06:41 GMT
Selling this heavily undervalued Stock at these low could be a big mistake but thats your decision . Should You Invest In Axsome Therapeutics? Monday, May 8, 2017 www.talkmarkets.com/content/stocks--equities/should-y… Final Thoughts Axsome is very interesting to me. The company has four active Phase 3 clinical trials with two drug candidates. AXS-05 targets a host of mechanisms in the CNS that are clinically and commercially proven to be effective for the treatment of depression and agitation. The concept with AXS-05 is that dextromethorphan is pretty darn effective in treating depression, but has such poor bioavailability that it is hardly used. Bupropion synergistically improves the uptake of BM while providing baseline antidepressant effects. AXS-02 is an oral formulation of a well know bisphosphonate known to improve pain in CRPS and knee OA. I like the fact that Axsome has good insider ownership, plenty of cash, drugs with proven mechanisms of action, strong IP, and plenty of catalysts. Data from COAST-1 is expected in the Q3-2017. That's the first catalyst up for the company. CREATE-1 and STRIDE-1 are up in the Q4-2017 and Q1-2018, respectively. If the company goes 3-for-3, this stock will be north of $15.
|
|
|
Post by JHam on May 9, 2017 13:28:50 GMT
Selling this heavily undervalued Stock at these low could be a big mistake but thats your decision . Should You Invest In Axsome Therapeutics? Monday, May 8, 2017 www.talkmarkets.com/content/stocks--equities/should-y… Final Thoughts Axsome is very interesting to me. The company has four active Phase 3 clinical trials with two drug candidates. AXS-05 targets a host of mechanisms in the CNS that are clinically and commercially proven to be effective for the treatment of depression and agitation. The concept with AXS-05 is that dextromethorphan is pretty darn effective in treating depression, but has such poor bioavailability that it is hardly used. Bupropion synergistically improves the uptake of BM while providing baseline antidepressant effects. AXS-02 is an oral formulation of a well know bisphosphonate known to improve pain in CRPS and knee OA. I like the fact that Axsome has good insider ownership, plenty of cash, drugs with proven mechanisms of action, strong IP, and plenty of catalysts. Data from COAST-1 is expected in the Q3-2017. That's the first catalyst up for the company. CREATE-1 and STRIDE-1 are up in the Q4-2017 and Q1-2018, respectively. If the company goes 3-for-3, this stock will be north of $15. It could also be a big mistake to hold through trial data results. You never know. I locked in a 14% profit on a stock, so I'm not sure how that could be a mistake. Even if it shoots to the moon before I get back in, I still wouldn't call it a mistake. I think we still have a quarter to go with this one at least before things really start to happen. We'll see. Good luck to us.
|
|
|
Post by bernstein on May 12, 2017 13:22:52 GMT
Aegis Capital has reiterated a ‘Buy’ rating and price target of $20 on Axsome Therapeutics (NASDAQ: AXSM) May 10, 2017 www.networknewswire.com/networknewsbreaks/networknewsbreaks-aegis-capital-reiterates-buy-rating-axsome-therapeutics-inc-nasdaq-axsm/Aegis Capital has reiterated a ‘Buy’ rating and price target of $20 on Axsome Therapeutics (NASDAQ: AXSM) after the company reported financial results for the quarter ended March 31, 2017. The analyst noted that although Axsome reported revenue in-line with consensus estimates, the focus remains on upcoming catalysts such as the company’s ongoing clinical trials. Since February 2017, the company’s AXS-05 has received fast track designation from the FDA for the treatment of Alzheimer’s disease (AD) agitation and treatment resistant depression (TRD). Topline data from the TRD treatment study is expected in the first quarter of 2018. Additionally, Axsome is developing AXS-02 in three separate phase 3 clinical programs, including chronic low back pain associated with modic changes and complex regional pain syndrome, with interim data expected in the fourth quarter of 2017, as well as knee osteoarthritis associated with bone marrow lesions, with interim data expected in the third quarter of 2017.
|
|
|
Post by bernstein on May 16, 2017 13:39:10 GMT
|
|
|
Post by bernstein on May 19, 2017 13:30:30 GMT
and another buy rating out today with tgt $14 thefly.com/landingPageNews.php?id=2555207&headline=AXSM-Axsome-Therapeutics-initiated-with-a-Buy-at-BTIGAxsome Therapeutics initiated with a Buy at BTIG BTIG analyst Robert Hazlett started coverage of Axsome with a $14 price target and a Buy rating. The analyst says that the company's AXS-05 combination is unique and could treat a number of disorders. He notes that data on the combination's impact on treatment-resistant depression is due in early 2018. Tgh analyst adds that the company's AXS-02 drug "is a novel approach to the treatment of pain," and reports that data on the drug is due out in Q3 and Q4.
|
|
|
Post by stargazer on May 20, 2017 3:46:29 GMT
Initiated a starter position yesterday @ 3.75
Bernstein thanks for identifying this one.
|
|
|
Post by bernstein on May 25, 2017 14:03:54 GMT
Another 1.9 Million shares bought by new institutional investors alone in this month . fintel.io/so/us/axsm
|
|
|
Post by bernstein on Jun 19, 2017 13:19:11 GMT
Fantastic new director appointed ,, she really must like what she sees at Axsome ... Axsome Therapeutics Appoints Myrtle Potter to its Board of Directors finance.yahoo.com/news/axsome-therapeutics-appoints-myrtle-potter-110000754.htmlMs. Potter was President, Commercial Operations and Chief Operating Officer of Genentech from 2000 to 2005, where she also served on the Executive Committee and was Co-Chair of the Product Portfolio Committee. At Genentech Ms. Potter led the commercialization of a number of products including Avastin™, Rituxan™, Herceptin™, Tarceva™, Xolair™, Nutropin™, Activase™, and TNkase™. Prior to joining Genentech, Ms. Potter was President of Bristol-Myers Squibb’s $3.5 billion, 3,500-person U.S. Cardiovascular and Metabolic Business. Before Bristol-Myers Squibb, Ms. Potter worked at Merck & Co. for fourteen years in roles of increasing responsibility, including Vice President of an $800 million U.S. pharmaceutical business unit. While at Merck, she started the joint venture entity Astra Merck, which through merger, later became AstraZeneca. She began her career with Procter and Gamble Patient Care Products. About Myrtle Potter myrtlepotterconsulting.com/myrtle-potter-and-company/myrtle-potter/
|
|
|
Post by JHam on Jun 19, 2017 17:22:05 GMT
Fantastic new director appointed ,, she really must like what she sees at Axsome ... Axsome Therapeutics Appoints Myrtle Potter to its Board of Directors finance.yahoo.com/news/axsome-therapeutics-appoints-myrtle-potter-110000754.htmlMs. Potter was President, Commercial Operations and Chief Operating Officer of Genentech from 2000 to 2005, where she also served on the Executive Committee and was Co-Chair of the Product Portfolio Committee. At Genentech Ms. Potter led the commercialization of a number of products including Avastin™, Rituxan™, Herceptin™, Tarceva™, Xolair™, Nutropin™, Activase™, and TNkase™. Prior to joining Genentech, Ms. Potter was President of Bristol-Myers Squibb’s $3.5 billion, 3,500-person U.S. Cardiovascular and Metabolic Business. Before Bristol-Myers Squibb, Ms. Potter worked at Merck & Co. for fourteen years in roles of increasing responsibility, including Vice President of an $800 million U.S. pharmaceutical business unit. While at Merck, she started the joint venture entity Astra Merck, which through merger, later became AstraZeneca. She began her career with Procter and Gamble Patient Care Products. About Myrtle Potter myrtlepotterconsulting.com/myrtle-potter-and-company/myrtle-potter/The market sure seems to like it.
|
|